C-(1-p-tolyl-cyclohexyl)-methylamine | 771582-88-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: C-(1-p-tolyl-cyclohexyl)-methylamine
• 英文别名: 1-[1-(4-Methylphenyl)cyclohexyl]methanamine；[1-(4-methylphenyl)cyclohexyl]methanamine
• CAS: 771582-88-8
• 化学式: C₁₄H₂₁N
• 分子量: 203.327
• InChiKey: FVVRLVQDXAZMHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-chloro-5-(6-methyl-pyridin-3-yl)-benzoic acid 、 C-(1-p-tolyl-cyclohexyl)-methylamine 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 3.67h， 生成 2-chloro-5-(6-methyl-pyridin-3-yl)-N-(1-p-tolyl-cyclohexylmethyl)-benzamide
  参考文献：
  名称：

  [EN] BENZAMIDE INHIBITORS OF THE P2X7 RECEPTOR
  [FR] INHIBITEURS BENZAMIDIQUES DU RECEPTEUR P2X7

  摘要：

  本发明提供了P2X7受体的苯甲酰胺抑制剂，其化学式为(I)，其中R1-R3如本文所定义。本发明的化合物在治疗IL-1介导的疾病方面具有用途，包括但不限于炎症性疾病，如骨关节炎和类风湿关节炎；过敏，哮喘，慢性阻塞性肺病，癌症，再灌注或缺血性中风或心脏病发作，自身免疫疾病和其他疾病。

  公开号：

  WO2004099146A1

文献信息

• Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
  申请人：Kelly G. Michael

  公开号：US20060217448A1

  公开（公告）日：2006-09-28

  Bicycloheteroaryl compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

  公开了具有以下公式代表的Bicycloheteroaryl化合物：这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如疼痛、炎症、创伤性损伤等。
• Benzamide, heteroarylamide and reverse amides
  申请人：Pfizer Inc.

  公开号：US20030186981A1

  公开（公告）日：2003-10-02

  The present invention relates to novel to P2X 7 inhibitors of formula I 1 and to processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in therapy. The active compounds of the present invention are potent inhibitors of P2X 7 and as such are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及一种新的P2X7抑制剂的I1式，以及其制备方法、制备中间体、含有它们的药物组合物，以及它们在治疗中的应用。本发明的活性化合物是P2X7的有效抑制剂，因此在治疗炎症、骨关节炎、类风湿关节炎、癌症、中风或心脏病发作中的再灌注或缺血、自身免疫疾病和其他疾病中具有用途。
• Fused heterocyclic compounds, and compositions and uses thereof
  申请人：Kelly G. Michael

  公开号：US20060258689A1

  公开（公告）日：2006-11-16

  Fused heterocyclic compounds are disclosed that have formula 1: where A, B, L, N, R 1 , R 3 , R 4′ , Y and Z are as defined herein. The compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.

  披露了具有以下式1的融合杂环化合物：其中A、B、L、N、R1、R3、R4'、Y和Z的定义如本文所述。该化合物及其药物组成物对哺乳动物包括人类的各种疾病的预防和治疗是有用的，包括但不限于疼痛、炎症、认知障碍、焦虑、抑郁等。
• [EN] CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS<br/>[FR] PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZÈNESULFONAMIDES CYCLIQUES, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES
  申请人：SANOFI AVENTIS

  公开号：WO2009080223A1

  公开（公告）日：2009-07-02

  The invention relates to cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What is described are compounds of the Formula (I), in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  该发明涉及环状N-[1,3,4]-噻二唑-2-基苯磺酰胺及其生理上可接受的盐和生理功能衍生物，显示出PPARδ或PPARδ和PPARγ激动剂活性。所描述的是Formula (I)的化合物，其中基团如所定义，并且它们的生理上可接受的盐及其制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍，以及胰岛素抵抗相关的疾病，以及中枢和外周神经系统的脱髓鞘化和其他神经退行性疾病。
• Benzamide inhibitors of the P2X7 receptor
  申请人：Dombroski A. Mark

  公开号：US20050009900A1

  公开（公告）日：2005-01-13

  The present invention provides benzamide inhibitors of the P2X 7 receptor of the formula: wherein R 1 -R 3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明提供了公式如下的P2X7受体的苯甲酰胺抑制剂：其中R1-R3如本文所定义。本发明的化合物在治疗IL-1介导的疾病方面具有用处，包括但不限于炎症性疾病，如骨关节炎和类风湿性关节炎；过敏、哮喘、慢性阻塞性肺疾病、癌症、中风或心脏病发作中的再灌注或缺血、自身免疫性疾病和其他疾病。